Louis LETINIER - Admis au titre de docteur

Doctorat Pharmacologie - Option pharmaco-épidémiologie, pharmaco-vigilance

Thèse soutenue le 3 mars 2022 - Université de Bordeaux

Ecole doctorale : Sociétés, Politique, Santé Publique

Sujet : Interactions médicamenteuses : étude de la prévalence et des risques encourus et développement d’outils de prévention

Mots-clés de la thèse : interactions médicamenteuses,pharmacovigilance,pharmaco-informatique,pharmaco-épidémiologie,bon usage du médicament,

Direction de thèse : Antoine PARIENTE

Unité de recherche : Bordeaux Population Health Research Center U 1219 - Bordeaux

Médecine - DES, Diplôme d'études spécialisées

obtenu en octobre 2017 - Université de Bordeaux
Option : santé publique et médecine sociale

Production scientifique

- Louis Letinier, Julien Jouganous, Mehdi Benkebil, Alicia Bel-Letoile, Clement Goehrs, Allison Singier, Franck Rouby, Clemence Lacroix, Ghada Miremont-Salame, Joelle Micallef, Francesco Salvo, Antoine Pariente 2021. Artificial intelligence for unstructured healthcare data: application to coding of patient reporting of adverse drug reactions Clinical Pharmacology and Therapeutics, , https://hal.archives-ouvertes.fr/hal-03273575/document
- Létinier L, Ferreira A, Marceron A, Babin M, Micallef J, Miremont-Salamé G and Pariente A 2021. Spontaneous Reports of Serious Adverse Drug Reactions Resulting From Drug–Drug Interactions: An Analysis From the French Pharmacovigilance Database Front. Pharmacol, 11:624562, https://www.frontiersin.org/articles/10.3389/fphar.2020.624562/full
- Antoine Pariente, Vanessa Labat, Yohann Mansiaux, Francesco Salvo, Bernard Begaud, E. Raschi, J. L. Faillie, Louis Letinier, Julien Bezin 2020. DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus Drug Safety, 43, pp.767-774,
- L. Larrouquere, M. Gabin, E. Poingt, A. Mouffak, A. Hlavaty, M. Lepelley, C. Khouri, A. Bellier, J. Alexandre, P. Bedouch, L. Bertoletti, R. Bordet, B. Bouhanick, Annie-Pierre Jonville-Bera, S. Laporte, C. Le Jeunne, Louis Letinier, J. Micallef, Florian Naudet, M. Roustit, Mathieu Molimard, V. Richard, J. L. Cracowski 2020. Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID-19 pandemic Fundamental and Clinical Pharmacology, 34, pp.389-396,
- Emilie Casarotto, Pernelle Noize, Louis Letinier, Francesco Salvo, Anne Pham-Ledard, Mathieu Molimard 2020. Safety Profile of Drugs for Advanced Melanoma: A Report Based on 2008 to 2018 United States Food and Drug Administration Data British Journal of Clinical Pharmacology, ,
- Louis Letinier, Sebastien Cossin, Yohann Mansiaux, Mickael Arnaud, Francesco Salvo, Julien Bezin, Frantz Thiessard, Antoine Pariente 2019. Risk of Drug-Drug Interactions in Out-Hospital Drug Dispensings in France: Results From the DRUG-Drug Interaction Prevalence Study Frontiers in Pharmacology, 10, pp.265, https://hal.archives-ouvertes.fr/hal-03211472/document
- J. Perino, Louis Letinier, Clement Mathieu, Annie Fourrier-Reglat, Ghada Miremont-Salame, S. Qchiqach, Christophe Tzourio, Amélie Daveluy 2018. Consumption of psychoactive substances: an overview of students in the i-Share cohort Thérapie, 73, pp.575-575,
- Louis Letinier, Yohann Mansiaux, Antoine Pariente, Annie Fourrier-Reglat 2018. Impact of cancer diagnosis on persistence of oral antidiabetic drugs Diabetes Research and Clinical Practice, 139, pp.323-330,
- Amélie Daveluy, H. Geniaux, Marie Baumevieille, Louis Letinier, M. N. Matta, A. Lazes-Charmetant, Francoise Haramburu, P. Gueroult 2018. Parachuting psychoactive substances: Pharmacokinetic clues for harm reduction Addictive Behaviors, 78, pp.173-177,
- Thomas Grellety, Sophie Cousin, Louis Letinier, Pauline Bosco-Levy, Stephanie Hoppe, Damien Joly, Nicolas Penel, Simone Mathoulin-Pelissier, Antoine Italiano 2016. Prognostic factor of early death in phase II trials or the end of 'sufficient life expectancy' as an inclusion criterion? (predit model) BMC Cancer, 16, pp.768, https://hal.univ-lille.fr/hal-02530714/document

Dernière mise à jour le 23 novembre 2021